Adherex Technologies (NASDAQ:FENC – Get Free Report) and Immix Biopharma (NASDAQ:IMMX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.
Valuation and Earnings
This table compares Adherex Technologies and Immix Biopharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adherex Technologies | $44.64 million | 8.21 | -$9.74 million | ($0.29) | -36.21 |
| Immix Biopharma | N/A | N/A | -$29.44 million | ($0.92) | -11.14 |
Volatility & Risk
Adherex Technologies has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500.
Institutional & Insider Ownership
55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by company insiders. Comparatively, 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Adherex Technologies and Immix Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adherex Technologies | 1 | 1 | 4 | 1 | 2.71 |
| Immix Biopharma | 1 | 1 | 7 | 0 | 2.67 |
Adherex Technologies currently has a consensus price target of $15.40, suggesting a potential upside of 46.67%. Immix Biopharma has a consensus price target of $20.67, suggesting a potential upside of 101.63%. Given Immix Biopharma’s higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Adherex Technologies.
Profitability
This table compares Adherex Technologies and Immix Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adherex Technologies | -17.12% | -43.87% | -11.35% |
| Immix Biopharma | N/A | -73.24% | -59.20% |
Summary
Adherex Technologies beats Immix Biopharma on 9 of the 14 factors compared between the two stocks.
About Adherex Technologies
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
About Immix Biopharma
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
